Gilead Sciences, Inc. (GILD) announced today its results of operations for the quarter ended March 31, 2014. Total revenues for the first quarter of 2014 increased to $5.00 billion from $2.53 billion for the first quarter of 2013, largely due …
Trending at Lumira Ventures
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
– Accelerates Development of All-Oral Regimen for the Treatment of HCV – – Leverages Gilead’s Infrastructure and Expertise in Antiviral Drug Development, Manufacturing and Commercialization – FOSTER CITY, Calif. & PRINCETON, N.J.–(BUSINESS WIRE)– Gilead Sciences, Inc. …
Pharmasset Announces Interim Data from an Ongoing 28-day Phase 2a Study with PSI-7977 for the Treatment of Chronic Hepatitis C Infection
Source : Pharmasset, Inc. PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ — Pharmasset, Inc. announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in …
Pharmasset Initiates First Time in Human Study of PSI-938 for the Treatment of Hepatitis C
Source : Pharmasset, Inc. PRINCETON, N.J., April 8 /PRNewswire-FirstCall/ — Pharmasset, Inc. announced today that dosing has initiated in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-938, a third generation purine nucleotide analog polymerase inhibitor of hepatitis …
Product developed by acquired Lumira Capital portfolio company, Corus, wins FDA approval
Gilead’s Inhaled Antibiotic for Lungs Wins Approval Feb. 22 (Bloomberg) — Gilead Sciences Inc., the world’s largest maker of HIV treatments, won U.S. approval of an inhaled antibiotic for lung infections in cystic fibrosis patients. The Food …
Pharmasset Announces Complete Enrollment of RG7128 Phase 2b Clinical Study
Learn More-External Link
Pharmasset Prices Underwritten Offering of Common Stock
Learn More-External Link
Pharmasset Initiates Phase 2a Trial with PSI-7977, a Chirally Pure Isomer of PSI-7851
Learn More-External Link
Roche and Pharmasset initiate dosing in Phase IIb hepatitis trial
Learn More-External Link